Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Abstract 3260: Potentiation of Type I interferon signaling leads to in vivo efficacy achieved with combination of chemotherapy and the PARP7 inhibitor RBN-2397

Kaiko Kunii, Jeff J. Song, Danielle Zimmerman, Chang Liu, Kristy G. Kuplast-Barr, Jonathan J. Novak, Sunaina P. Nayak, Joseph M. Gozgit, Melissa M. Vasbinder, Kristen McEachern, Kevin W. Kuntz, Heike Keilhack, Jennifer R. Molina

Cancer Res (2023) 83 (7_Supplement): 3260.

https://doi.org/10.1158/1538-7445.AM2023-3260

Published: 04 April 2023

View articletitled, Abstract 3260: Potentiation of Type I interferon signaling leads to in vivo efficacy achieved with combination of chemotherapy and the PARP7 inhibitor RBN-2397

Journal Articles

Abstract 1836: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors

Kristy Kuplast-Barr, Melissa L. Johnson, Manish R. Patel, Timothy A. Yap, Gerald S. Falchook, Patricia LoRusso, Ryan Abo, Chang Liu, Erika L. Manyak, Lisa Cleary, Viviana Bozon, Sudha Parasuraman, Heike Keilhack, Kristen McEachern

Cancer Res (2022) 82 (12_Supplement): 1836.

https://doi.org/10.1158/1538-7445.AM2022-1836

Published: 15 June 2022

View articletitled, Abstract 1836: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors

Journal Articles

Abstract 2154: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models

Cancer Res (2022) 82 (12_Supplement): 2154.

https://doi.org/10.1158/1538-7445.AM2022-2154

Published: 15 June 2022

View articletitled, Abstract 2154: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models

Journal Articles

Abstract 48: RBN-2397: A potent and selective small molecule inhibitor of PARP7 that induces tumor-derived antitumor immunity dependent on CD8 T cells

Cancer Res (2021) 81 (13_Supplement): 48.

https://doi.org/10.1158/1538-7445.AM2021-48

Published: 01 July 2021

View articletitled, Abstract 48: RBN-2397: A potent and selective small molecule inhibitor of PARP7 that induces tumor-derived antitumor immunity dependent on CD8 T cells

Journal Articles

Abstract 381: Elevated PARP7 expression in select cancers identifies a target population for RBN-2397 therapy

Jodie Wong, Kristy Kuplast-Barr, Ryan P. Abo, Anupriya S. Kulkarni, Linda T. Nieman, Azfar Neyaz, Katherine H. Xu, Radwa Sharaf, Lee A. Albacker, David T. Ting, Heike Keilhack, Kristen A. McEachern

Cancer Res (2021) 81 (13_Supplement): 381.

https://doi.org/10.1158/1538-7445.AM2021-381

Published: 01 July 2021

View articletitled, Abstract 381: Elevated PARP7 expression in select cancers identifies a target population for RBN-2397 therapy

Journal Articles

Abstract 1344: Small molecule inhibitor of CD38 modulates its intra- and extracellular functions leading to antitumor activity

Prashant Shambharkar, Danielle J. Blackwell, Melissa M. Vasbinder, Laurie B. Schenkel, Kaiko Kunii, Jenkins L. Lemera, Kristy G. Kuplast-Barr, Yue Ren, Ellen Bamberg, W. David Church, Christina R. Majer, Luke Utley, Kristen McEachern, Mario Niepel, Tim J. Wigle, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack, Joseph M. Gozgit

Cancer Res (2021) 81 (13_Supplement): 1344.

https://doi.org/10.1158/1538-7445.AM2021-1344

Published: 01 July 2021

View articletitled, Abstract 1344: Small molecule inhibitor of CD38 modulates its intra- and extracellular functions leading to antitumor activity

Journal Articles

Abstract 1021: Investigating the mechanism of PARP7 inhibition in type I interferon signaling by arrayed CRISPR screening

Bin Gui, Ryan Abo, Patrick Flynn, Alvin Z. Lu, Jan-Rung Mo, Joseph M. Gozgit, Melissa M. Vasbinder, Zacharenia A. Varsamis, Andrew Santospago, Victoria M. Richon, Kevin W. Kuntz, Heike Keilhack, Timothy J. Mitchison, Mario Niepel

Cancer Res (2021) 81 (13_Supplement): 1021.

https://doi.org/10.1158/1538-7445.AM2021-1021

Published: 01 July 2021

View articletitled, Abstract 1021: Investigating the mechanism of PARP7 inhibition in type I interferon signaling by arrayed CRISPR screening

Journal Articles

Abstract 1348: Targeted degradation of PARP14 Using a heterobifunctional small molecule

Cancer Res (2021) 81 (13_Supplement): 1348.

https://doi.org/10.1158/1538-7445.AM2021-1348

Published: 01 July 2021

View articletitled, Abstract 1348: Targeted degradation of PARP14 Using a heterobifunctional small molecule

Journal Articles

Abstract 3405: PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition leads to tumor regression

Cancer Res (2020) 80 (16_Supplement): 3405.

https://doi.org/10.1158/1538-7445.AM2020-3405

Published: 15 August 2020

View articletitled, Abstract 3405: PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition leads to tumor regression

Journal Articles

Abstract 1038: A potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants

Laurie Schenkel, Jennifer Molina, Kerren Swinger, Ryan Abo, Danielle Blackwell, Anne Cheung, William Church, Kristy Kuplast-Barr, Alvin Lu, Elena Minissale, Mario Niepel, Melissa Vasbinder, Tim Wigle, Victoria Richon, Heike Keilhack, Kevin Kuntz

Cancer Res (2020) 80 (16_Supplement): 1038.

https://doi.org/10.1158/1538-7445.AM2020-1038

Published: 15 August 2020

View articletitled, Abstract 1038: A potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants

Journal Articles

Abstract 4381: A multi-omic characterization of PARP enzymes in cancer to identify novel monoPARP drug targets

Ryan P. Abo, Mario Niepel, Heike Keilhack

Cancer Res (2020) 80 (16_Supplement): 4381.

https://doi.org/10.1158/1538-7445.AM2020-4381

Published: 15 August 2020

View articletitled, Abstract 4381: A multi-omic characterization of PARP enzymes in cancer to identify novel monoPARP drug targets

Journal Articles

Abstract 506: A bespoke screening platform to study mono(ADP-ribosylation)

Tim J. Wigle, Danielle J. Blackwell, Laurie B. Schenkel, Yue Ren, William D. Church, Hetvi J. Desai, Kerren K. Swinger, Andrew G. Santospago, Christina R. Majer, Alvin Z. Lu, Mario Niepel, Nicholas R. Perl, Melissa M. Vasbinder, Heike Keilhack, Kevin W. Kuntz

Cancer Res (2020) 80 (16_Supplement): 506.

https://doi.org/10.1158/1538-7445.AM2020-506

Published: 15 August 2020

View articletitled, Abstract 506: A bespoke screening platform to study mono(ADP-ribosylation)

Journal Articles

Abstract DDT02-01: RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways

Cancer Res (2020) 80 (16_Supplement): DDT02-01.

https://doi.org/10.1158/1538-7445.AM2020-DDT02-01

Published: 15 August 2020

View articletitled, Abstract DDT02-01: RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways

Journal Articles

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming

Cancer Res (2017) 77 (23): 6651–6666.

https://doi.org/10.1158/0008-5472.CAN-17-0899

Published: 30 November 2017

View articletitled, EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming

Includes: Supplementary data

Journal Articles

Abstract 137: Development and application of a 62-gene panel for assessment of somatic sequence and structural variants in tumor DNA derived from non-Hodgkin lymphoma patients treated in a phase 1 clinical trial with the EZH2 inhibitor tazemetostat

Scott R. Daigle, Samuel Angiuoli, Sian Jones, Scott Ribich, Heike Keilhack, Mark Sausen, Peter T. Ho, Stephen J. Blakemore

Cancer Res (2016) 76 (14_Supplement): 137.

https://doi.org/10.1158/1538-7445.AM2016-137

Published: 15 July 2016

View articletitled, Abstract 137: Development and application of a 62-gene panel for assessment of somatic sequence and structural variants in tumor DNA derived from non-Hodgkin lymphoma patients treated in a phase 1 clinical trial with the EZH2 inhibitor tazemetostat

Journal Articles

Abstract 4520: The effect of EPZ011989, an enhancer of Zeste homolog 2 inhibitor, in acute myeloid leukemia

Sydney Fobare, Cecelia Miller, Shelley J. Orwick, Heike Keilhack, Erin Hertlein, John C. Byrd

Cancer Res (2016) 76 (14_Supplement): 4520.

https://doi.org/10.1158/1538-7445.AM2016-4520

Published: 15 July 2016

View articletitled, Abstract 4520: The effect of EPZ011989, an enhancer of Zeste homolog 2 inhibitor, in acute myeloid leukemia

Journal Articles

Abstract 312: Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma

Carly T. Campbell, Jeff S. Jasper, Scott R. Daigle, Scott A. Ribich, Heike Keilhack, Jesse S. Smith, Peter T. Ho, Stephen J. Blakemore

Cancer Res (2016) 76 (14_Supplement): 312.

https://doi.org/10.1158/1538-7445.AM2016-312

Published: 15 July 2016

View articletitled, Abstract 312: Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma

Journal Articles

PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models

Cancer Res (2011) 71 (8): 3052–3065.

https://doi.org/10.1158/0008-5472.CAN-10-2282

Published: 13 April 2011

View articletitled, PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models

Includes: Supplementary data

Journal Articles

Abstract 4561: Quantitative phosphoproteomics of an AKT inhibitor in a PTEN-LOF breast model by label free phospho-dMS demonstrates modulation of protein transcription, protein translation, and motility

An Chi, Heike Keilhack, Hongbo Guo, Kumiko Nagashima, Jannik Andersen, Cloud Paweletz, Ronald Hendrickson

Cancer Res (2010) 70 (8_Supplement): 4561.

https://doi.org/10.1158/1538-7445.AM10-4561

Published: 15 April 2010

View articletitled, Abstract 4561: Quantitative phosphoproteomics of an AKT inhibitor in a PTEN-LOF breast model by label free phospho-dMS demonstrates modulation of protein transcription, protein translation, and motility

Journal Articles

Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

Cancer Res (2004) 64 (24): 8816–8820.

https://doi.org/10.1158/0008-5472.CAN-04-1923

Published: 16 December 2004

View articletitled, Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 3260: Potentiation of Type I interferon signaling leads to in vivo efficacy achieved with combination of chemotherapy and the PARP7 inhibitor RBN-2397

Abstract 1836: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors

Abstract 2154: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models

Abstract 48: RBN-2397: A potent and selective small molecule inhibitor of PARP7 that induces tumor-derived antitumor immunity dependent on CD8 T cells

Abstract 381: Elevated PARP7 expression in select cancers identifies a target population for RBN-2397 therapy

Abstract 1344: Small molecule inhibitor of CD38 modulates its intra- and extracellular functions leading to antitumor activity

Abstract 1021: Investigating the mechanism of PARP7 inhibition in type I interferon signaling by arrayed CRISPR screening

Abstract 1348: Targeted degradation of PARP14 Using a heterobifunctional small molecule

Abstract 3405: PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition leads to tumor regression

Abstract 1038: A potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants

Abstract 4381: A multi-omic characterization of PARP enzymes in cancer to identify novel monoPARP drug targets

Abstract 506: A bespoke screening platform to study mono(ADP-ribosylation)

Abstract DDT02-01: RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming

Abstract 137: Development and application of a 62-gene panel for assessment of somatic sequence and structural variants in tumor DNA derived from non-Hodgkin lymphoma patients treated in a phase 1 clinical trial with the EZH2 inhibitor tazemetostat

Abstract 4520: The effect of EPZ011989, an enhancer of Zeste homolog 2 inhibitor, in acute myeloid leukemia

Abstract 312: Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma

PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models

Abstract 4561: Quantitative phosphoproteomics of an AKT inhibitor in a PTEN-LOF breast model by label free phospho-dMS demonstrates modulation of protein transcription, protein translation, and motility

Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only